A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of DVS SR in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder

Trial Profile

A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of DVS SR in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2014

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
    • 09 Jan 2012 Actual patient number is changed from 463 to 439 according to ClinicalTrials.gov.
    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top